Harrow (HROW) Competitors $24.96 +0.20 (+0.79%) As of 10:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HROW vs. ZLAB, AKRO, MRUS, MOR, PTGX, CRNX, OGN, CPRX, VKTX, and XENEShould you be buying Harrow stock or one of its competitors? The main competitors of Harrow include Zai Lab (ZLAB), Akero Therapeutics (AKRO), Merus (MRUS), MorphoSys (MOR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), Organon & Co. (OGN), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical preparations" industry. Harrow vs. Zai Lab Akero Therapeutics Merus MorphoSys Protagonist Therapeutics Crinetics Pharmaceuticals Organon & Co. Catalyst Pharmaceuticals Viking Therapeutics Xenon Pharmaceuticals Zai Lab (NASDAQ:ZLAB) and Harrow (NASDAQ:HROW) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings. Which has preferable valuation and earnings, ZLAB or HROW? Harrow has lower revenue, but higher earnings than Zai Lab. Harrow is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZai Lab$398.99M8.63-$334.62M-$2.59-12.08Harrow$199.61M4.46-$24.41M-$0.44-56.74 Is ZLAB or HROW more profitable? Harrow has a net margin of -19.75% compared to Zai Lab's net margin of -76.14%. Zai Lab's return on equity of -36.97% beat Harrow's return on equity.Company Net Margins Return on Equity Return on Assets Zai Lab-76.14% -36.97% -27.10% Harrow -19.75%-45.57%-8.87% Do insiders and institutionals believe in ZLAB or HROW? 41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 13.9% of Zai Lab shares are owned by company insiders. Comparatively, 13.7% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts recommend ZLAB or HROW? Zai Lab presently has a consensus target price of $47.37, indicating a potential upside of 51.43%. Harrow has a consensus target price of $60.50, indicating a potential upside of 142.34%. Given Harrow's stronger consensus rating and higher probable upside, analysts clearly believe Harrow is more favorable than Zai Lab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zai Lab 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Harrow 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to ZLAB or HROW? In the previous week, Zai Lab had 8 more articles in the media than Harrow. MarketBeat recorded 12 mentions for Zai Lab and 4 mentions for Harrow. Harrow's average media sentiment score of 1.39 beat Zai Lab's score of 0.76 indicating that Harrow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, ZLAB or HROW? Zai Lab has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Harrow has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Does the MarketBeat Community prefer ZLAB or HROW? Zai Lab received 138 more outperform votes than Harrow when rated by MarketBeat users. Likewise, 64.53% of users gave Zai Lab an outperform vote while only 59.62% of users gave Harrow an outperform vote. CompanyUnderperformOutperformZai LabOutperform Votes23164.53% Underperform Votes12735.47% HarrowOutperform Votes9359.62% Underperform Votes6340.38% SummaryZai Lab and Harrow tied by winning 9 of the 18 factors compared between the two stocks. Get Harrow News Delivered to You Automatically Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HROW vs. The Competition Export to ExcelMetricHarrowPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$890.82M$6.75B$5.51B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-26.587.3222.5518.49Price / Sales4.46239.19394.97102.66Price / CashN/A65.8538.1834.62Price / Book12.426.436.694.25Net Income-$24.41M$143.21M$3.22B$248.31M7 Day Performance-0.42%1.24%1.11%1.12%1 Month Performance-0.06%6.09%3.59%3.68%1 Year Performance139.36%-3.34%15.65%5.19% Harrow Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HROWHarrow2.3419 of 5 stars$24.97+0.8%$60.50+142.3%+143.1%$890.82M$199.61M-26.58182Positive NewsGap DownZLABZai Lab2.173 of 5 stars$29.71+3.0%$47.37+59.4%+100.6%$3.26B$398.99M-10.731,950Upcoming EarningsPositive NewsAKROAkero Therapeutics3.7969 of 5 stars$37.67+0.1%$76.29+102.5%+129.3%$3.00BN/A-10.0530Insider TradeNews CoveragePositive NewsMRUSMerus3.4294 of 5 stars$43.23+0.4%$85.31+97.3%+1.3%$2.99B$36.13M-10.9437Upcoming EarningsAnalyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730PTGXProtagonist Therapeutics3.4698 of 5 stars$45.80-1.0%$65.44+42.9%+82.5%$2.81B$434.43M17.22120Upcoming EarningsNews CoveragePositive NewsCRNXCrinetics Pharmaceuticals3.6563 of 5 stars$30.15-0.9%$73.00+142.1%-23.8%$2.81B$1.04M-8.08210Upcoming EarningsNews CoveragePositive NewsOGNOrganon & Co.4.7614 of 5 stars$10.67-4.0%$20.60+93.1%-30.5%$2.75B$6.40B3.2010,000Gap DownCPRXCatalyst Pharmaceuticals4.6728 of 5 stars$22.02-2.2%$32.29+46.6%+61.4%$2.69B$491.73M18.6680Upcoming EarningsNews CoveragePositive NewsVKTXViking Therapeutics4.4914 of 5 stars$23.72-0.9%$89.75+278.4%-63.7%$2.66BN/A-23.7220Analyst ForecastOptions VolumeAnalyst RevisionXENEXenon Pharmaceuticals2.5924 of 5 stars$34.70-1.2%$56.78+63.6%-6.0%$2.66B$9.43M-12.30210Upcoming EarningsOptions VolumePositive News Related Companies and Tools Related Companies Zai Lab Alternatives Akero Therapeutics Alternatives Merus Alternatives MorphoSys Alternatives Protagonist Therapeutics Alternatives Crinetics Pharmaceuticals Alternatives Organon & Co. Alternatives Catalyst Pharmaceuticals Alternatives Viking Therapeutics Alternatives Xenon Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HROW) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HROW Stock Free HROW Stock Alerts